Brain Atrophy in Multiple Sclerosis: Clinical Relevance and Technical Aspects

Jaume Sastre-Garriga, Deborah Pareto, Àlex Rovira

Research output: Contribution to journalReview articleResearchpeer-review

45 Citations (Scopus)


© 2017 Elsevier Inc. There is evidence of a neurodegenerative process running in parallel with or as a consequence of the inflammatory phenomenon in multiple sclerosis (MS). MR imaging has been central in the generation of such knowledge and has played a pivotal role in investigating the neurodegenerative process. However, there is insufficient evidence supporting MR imaging–measured brain atrophy as a biomarker of the neurodegenerative component of MS in the daily care of patients with MS. This article discusses the prognostic value of brain volume measurements and their potential role in monitoring treatment response in patients with MS.
Original languageEnglish
Pages (from-to)289-300
JournalNeuroimaging Clinics of North America
Issue number2
Publication statusPublished - 1 May 2017


  • Biological confounding factors
  • Brain atrophy
  • Disability
  • Gray matter
  • MR imaging
  • Multiple sclerosis


Dive into the research topics of 'Brain Atrophy in Multiple Sclerosis: Clinical Relevance and Technical Aspects'. Together they form a unique fingerprint.

Cite this